Frontier Capital Management’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Frontier Capital Management’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-98,759	Closed	-$1.6M	–	335
2017 Q1	$1.6M	Sell	98,759 -1,425	-1%	-$20.6K	0.01%	284
2016 Q4	$1.51M	Sell	100,184 -6,397	-6%	-$90.3K	0.01%	279
2016 Q3	$1.62M	Buy	106,581 +24,582	+30%	+$994K	0.01%	285
2016 Q2	$3.18M	Sell	81,999 -111,615	-58%	-$4.01M	0.03%	278
2016 Q1	$5.38M	Sell	193,614 -115,080	-37%	-$3.84M	0.04%	269
2015 Q4	$16.6M	Buy	+308,694	New	+$15.6M	0.14%	206

Other funds holding ITCI

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

HIM

Hillhouse Investment Management Grand Cayman, Cayman Islands $3.13B AUM 7.29% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

RPAM

Rhenman & Partners Asset Management Stockholm, Sweden $1.06B AUM 52.03% 1-Year Est. Return

Frontier Capital Management's ITCI Position: Q2 2017 in Review

Frontier Capital Management sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2017, closing a stake of 98,759 shares — an estimated $1.6M sold.

Frontier Capital Management first reported a position in ITCI in Q4 2015 and held it in 6 quarters. The position peaked at $16.6M in Q4 2015. 100 funds tracked by Wall St. Rank hold ITCI as of Q2 2017.

Frontier Capital Management reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2017 after selling out during the quarter.
Frontier Capital Management sold 98,759 Intra-Cellular Therapies Inc. shares in Q2 2017, an estimated $1.6M.
Frontier Capital Management first reported a position in Intra-Cellular Therapies Inc. in Q4 2015 and held it in 6 quarters.
Frontier Capital Management's Intra-Cellular Therapies Inc. position peaked at $16.6M in Q4 2015.
100 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2017.

Based on Frontier Capital Management's 13F filing for Q2 2017, filed 4 Aug 2017.